☰

Robert B. Diasio

Affiliations: 
University of Alabama, Birmingham, Birmingham, AL, United States 
Area:
Pharmacology, Genetics, Toxicology, Biomedical Engineering
Google:
"Robert Diasio"
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor

Children

Sign in to add trainee
Carmelo Blanquicett grad student 2005 UAB
Lori K. Mattison grad student 2006 UAB
Xue Zhang grad student 2006 UAB

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Chakravarthy AB, Zhao F, Meropol NJ, et al. (2019) Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). The Oncologist
Etienne-Grimaldi M, Cozic N, Boyer J, et al. (2019) FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity Annals of Oncology. 30: v214
Beumer JH, Chu E, Allegra C, et al. (2018) Therapeutic Drug Monitoring in Oncology: IATDMCT Recommendations for 5-Fluorouracil Therapy. Clinical Pharmacology and Therapeutics
Siddiqui NS, Purvey S, Hamal R, et al. (2018) Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades. Journal of Clinical Oncology. 36: 2576-2576
Wu R, Nie Q, Kubica PA, et al. (2018) Abstract 911: Targeting the mutant KRAS/BRAF-induced enhancer as an approach to overcome resistance to 5-fluorouracil-based chemotherapy in colorectal cancer Cancer Research. 78: 911-911
Nie Q, Shrestha S, Tapper EE, et al. (2018) Abstract 3893: Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity Cancer Research. 78: 3893-3893
Jaffee EM, Dang CV, Agus DB, et al. (2017) Future cancer research priorities in the USA: a Lancet Oncology Commission. The Lancet. Oncology. 18: e653-e706
Nie Q, Shrestha S, Tapper EE, et al. (2017) Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity. Clinical Pharmacology and Therapeutics
Flores JP, Diasio RB, Saif MW. (2017) Drug metabolism and pancreatic cancer. Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology. 30: 54-61
Elraiyah T, Jerde CR, Shrestha S, et al. (2016) Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. Clinical Pharmacology and Therapeutics
See more...